Insulin-like growth factor-1 and lean body mass in HIV-infected children

What Was Tested

This clinical trial paper looks at IGF-1 LR3.

To describe insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-1-binding protein-1 (IGFBP-1) and IGFBP-3 in HIV+ children before and after initiating or changing antiretroviral therapy and to evaluate association of growth and body composition to growth factors at baseline and over time.

Who Took Part

PubMed indexes the participants as infants, young children and children, both men and women.

Ninety-seven prepubertal HIV+ children aged 1 month to younger than 13 years were observed over 48 weeks after beginning or changing antiretroviral therapy.

Anthropometric measures were compared as follows: subjects vs matched children from (a) the National Health and Nutrition Examination Survey to generate z scores and (b) HIV-exposed, uninfected children from Women and Infants Transmission Study; and subjects with normal vs abnormal IGF-1 and IGFBP concentrations at baseline.

How the Study Was Run

The methods mention a period of 48 weeks.

Serum IGF-1, IGFBP-1, and IGFBP-3 were measured and compared with age- and sex-specific norms.

Anthropometric changes were compared for children whose IGF-1 level normalized vs remaining subjects.

Multivariate analysis adjusting for sex, race, and baseline age evaluated associations between anthropometry and IGF-1 and IGFBP concentrations.

What Was Measured

Topics PubMed links to this paper include Anti-Retroviral Agents, Body Height, Child Development, Cohort Studies, Growth, HIV Infections and HIV-1.

What This Means in Plain Language

This is a clinical trial of IGF-1 LR3 over 48 weeks.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Journal of acquired immune deficiency syndromes (1999)), a journal based in United States.

More context: the IGF-1 LR3 compound page, all human trials.